China and UK health officials exchange views on drug supervision and cooperation
On the morning of August 16,2017, Wu Zhen, vice minister of the China Food and Drug Administration (CFDA), met with visiting Dr Ian Hudson, the chief executive of the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), and his delegation.
Both sides reviewed the Sino-Britain favorable cooperation in the field of drug supervision in recent years, in-depth exchanges of the two ministries to encourage innovation, promote industrial development, deepen the reform in the field of drug and medical device review and approval system initiatives, and exchanged opinions on further deepening the cooperation. Relevant directors of CFDA's related departments attended the meeting.
China’s President Xi urges accelerated building of medical system
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze